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lzheimer’s amyloid precursor protein 695 (APP) is a
plasma membrane protein, which is known to be
the source of the toxic amyloid 
 
 
 
 (A
 
 
 
) peptide asso-
ciated with the pathogenesis of Alzheimer’s disease (AD).
Here we demonstrate that by virtue of its chimeric NH
 
2
 
-
terminal signal, APP is also targeted to mitochondria of
cortical neuronal cells and select regions of the brain of a
transgenic mouse model for AD. The positively charged
residues at 40, 44, and 51 of APP are critical components
of the mitochondrial-targeting signal. Chemical cross-linking
together with immunoelectron microscopy show that the
mitochondrial APP exists in NH
 
2
 
-terminal inside trans-
A
 
membrane orientation and in contact with mitochondrial
translocase proteins. Mutational studies show that the
acidic domain, which spans sequence 220–290 of APP,
causes the transmembrane arrest with the COOH-terminal
73-kD portion of the protein facing the cytoplasmic side.
Accumulation of full-length APP in the mitochondrial com-
partment in a transmembrane-arrested form, but not lacking
the acidic domain, caused mitochondrial dysfunction and
impaired energy metabolism. These results show, for the
ﬁrst time, that APP is targeted to neuronal mitochondria
under some physiological and pathological conditions.
 
Introduction
 
Alzheimer’s disease (AD)* is a progressive neurodegenerative
disorder involving a number of cellular and biochemical lesions
(Mecocci et al., 1996; Sims, 1996; Beal, 1998; Selkoe,
1999). AD is characterized by the deposition of extracellular
plaques, which consist of 40–42-amino acid-long amyloid 
 
 
 
(A
 
 
 
) peptides and intracellular neurofibrilary tangles (Price
and Sisodia, 1998; Selkoe, 1999). A
 
 
 
 peptide is generated
from the COOH-terminal end of amyloid precursor protein
(APP) by the sequential action of 
 
 
 
 and 
 
 
 
 secretases (Siso-
dia and St George-Hyslop, 2002). The plasma membrane
(PM)–anchored APP in an NH
 
2
 
 terminus-out and COOH
terminus-in orientation (Nunan and Small, 2000) is shown
to be the substrate for the 
 
 
 
-secretase–mediated processing.
 
The precise cellular site for the 
 
 
 
-secretase–mediated processing
remains unclear. The familial or inherited AD, which mani-
fests at an early age, is often associated with mutations in
APP, whereas the sporadic form, which manifests at later
stages of life, is reported to be multifactorial, including induced
expression of APP (Cohen et al., 1988; Palmert et al., 1988;
Jacobsen et al., 1991; Rockenstein et al., 1995). Some studies
implicate environmental and/or endogenous factors in the
pathogenesis of sporadic AD (for review see Hugon et al.,
1999). Furthermore, expression of APP is induced by patho-
logical stimuli, environmental factors, and deprivation of
tropic factors (Stephenson et al., 1992; Hugon et al., 1999;
Shepherd et al., 2000), although intracellular distribution of
APP under these conditions remains unknown.
Intracellular lesions, including impairment of mitochondrial
energy metabolism, are associated with AD (Sims, 1996;
Beal, 1998). A decrease in energy metabolism and altered
cytochrome c oxidase (CytOX) activity are among the earliest
detectable defects in AD (Parker, 1991; De La Monte et al.,
2000; Maurer et al., 2000; Valla et al., 2001). Association
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of APP with the mitochondrial membrane fraction of AD
brains was observed in one study (Yamaguchi et al., 1992),
though the precise nature of association or its role in mito-
chondrial functions were not investigated.
Recently, we showed that xenobiotic inducible cyto-
chromes P4501A1, P4502B1, and P4502E1 proteins con-
tain NH
 
2
 
-terminal chimeric signals, which enable the bi-
modal targeting of these predominantly ER proteins to
mitochondria as well (Addya et al., 1997; Anandatheertha-
varada et al., 1999; Robin et al., 2002). The NH
 
2
 
-terminal
signal sequence of APP resembles the chimeric signals of
P4501A1, P4502B1, and P4502E1. We therefore set out to
investigate if APP is targeted to mitochondria in addition to
the PM. Using human cortical neuronal (HCN-1A) cells,
which exhibit in vivo neuronal functions (Ronnett et al.,
1990; Dunn et al., 1996), and a transgenic mouse model for
AD, we show that human neuronal APP695 is targeted to
both the PM and mitochondria. Our results also show that
the mitochondrial-targeted APP occurs in a transmembrane-
arrested orientation, which affects mitochondrial function
and energy metabolism.
 
Results
 
Dual localization of APP in human neuronal 
HCN-1A cells
 
A comparison of NH
 
2
 
-terminal chimeric sequences of APP
with those of P4501A1 and P4502B1 is shown in Fig. 1 A.
 
The NH
 
2
 
-terminal 38–amino acid region of APP with a hy-
drophobic helical structure functions as the ER-targeting
domain (Fig. 1 A). Immediately COOH terminal to this re-
gion contains positively charged residues at positions 40, 44,
and 51 that mimic the cryptic mitochondrial-targeting sig-
nals of P4501A1 and P4502B1 (Fig. 1 A). The positively
charged residues within sequence 20–30 of P4502B1 and se-
quence 32–44 of P4501A1 have been shown to be critical
for mitochondrial targeting (Addya et al., 1997; Anan-
datheerthavarada et al., 1999).
The purity of subcellular fractions was established by im-
munoblot analysis of various membrane fractions from
HCN-1A cells using antibodies to Na
 
 
 
/K
 
 
 
 ATPase (PM
specific), TOM40 (mitochondria specific), calreticulin (ER
specific), 
 
 
 
COP (Golgi specific), and p97 (nuclear specific)
as markers (Fig. 1 B). Immunoblot analysis using APP Nt
Ab (antibody specific for the NH
 
2
 
-terminal amino acids
42–66) in the bottom panel of Fig. 1 B shows the endoge-
nous levels of 95-kD APP in mitochondria and 
 
 
 
110-kD
APP in the PM, ER, as well as Golgi fractions of HCN
cells. PMA, a known inducer of APP expression (Ringheim
et al., 1996), was used to test the effects of elevated APP on
mitochondrial targeting. Northern blot analysis (Fig. 1 C)
shows that 
 
 
 
2.1-kb APP695 mRNA was induced at 12 and
24 h of PMA treatment (Fig. 1 C). Although not shown,
mRNAs for APP770, APP751, and APLP2 were not detect-
able by the Northern blot using isoform-specific probes
(Shepherd et al., 2000). These results suggest that HCN-1A
Figure 1. Chimeric signal properties of APP and its bimodal targeting to mitochondria and PMs. (A) Chimeric signals of APP and comparison 
with the signal domains of P4501A1 and 2B1. The ER-targeting sequence (1–36) of APP is indicated as a dark shaded area. Sequence 36–61 
with three positively charged residues (at positions 40, 44, and 51), the predicted mitochondrial-targeting sequence, and the mutant construct 
3M/APP carrying mutations at these positions are shown. (B) Immunoblot analysis of marker proteins for different subcellular fractions (50  g 
protein each) using antibodies to Na
 /K
  ATPase, TOM40, calreticulin,  COP, and p97. The bottom panel represents 200  g protein from 
each membrane fraction and was developed with APP Nt Ab. (C) Northern blot analysis of total RNA (25  g RNA each) from HCN cells treated with 
PMA for different time intervals. Hybridization with 18S DNA probe served as a loading control. (D) Western blot analysis of mitochondria 
and PM proteins (200  g protein each) from HCN cells treated with PMA for different time intervals using APP Nt Ab. (E) Measurement of 
reduction of MTT dye by freshly isolated mitochondria from HCN-1A cells treated with PMA for various time points was performed as described 
in the Materials and methods. (F) Immunoblot analysis of glycosidase-treated proteins (200  g each) from PMA (100 nM)-induced HCN cells 
using APP Nt Ab. Treatment with glycosidases was performed as described in the Materials and methods. Mito, mitochondria.T
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cells express predominantly the APP695 species. Consistent
with induced mRNA levels, the antibody-reactive protein
in both PM and mitochondria increased by 10–15-fold by
PMA treatment (Fig. 1 D). At 24 h of treatment, the mito-
chondrial level was nearly 60% of that detected in the PM.
Coincident with increased mitochondrial accumulation of
APP, the ability of mitochondria to reduce methylthiazole-
tetrazolium (MTT), which is widely used as a measure of
mitochondrial function, was also progressively diminished
(Fig. 1 E).
Immunoblot in Fig. 1 F shows that the 110-kD protein as-
sociated with the PM is converted to a 95-kD species after
treatment with glycosidases (PNGase F and 
 
O
 
-glycanase).
APP associated with the mitochondrial fraction, on the other
hand, did not show any difference in size by these treat-
ments. These results show that a substantial amount (
 
 
 
25–
30%) of induced APP695 protein exists in association with
the mitochondrial fraction in a nonglycosylated form.
 
The chimeric NH
 
2
 
-terminal signal of APP 
and its incomplete translocation through 
mitochondrial membranes
 
The nature of mitochondrial targeting of APP695 was fur-
ther studied using an in vitro mitochondrial import assay,
in which protection against limited proteolytic digestion
was used as a criterion for the import of 
 
35
 
S-labeled proteins
into mitochondria. Fig. 2 A (lane 1) shows that a full-length
APP of 95 kD is recovered in a reisolated mitochondrial
fraction after in vitro incubation, suggesting that APP in-
deed associates with mitochondrial membrane. Trypsin
treatment of in vitro–incubated mitochondria resulted in
the protection of a 22-kD fragment of APP (Fig. 2 A, lane
2). These results suggest that the 22-kD protected region
of APP is located inside the mitochondrial membrane,
whereas the remaining 
 
 
 
73-kD portion might be exposed
outside. Under similar import conditions, however, the
full-length P4501A1 and 2B1 proteins were protected, in-
dicating their complete translocation (Fig. 2 B). Both APP
binding to mitochondria and partial internalization were
markedly inhibited by uncouplers of mitochondrial mem-
brane potential, CCCP and 2,4 DNP, and also by mito-
chondrial swelling (Fig. 2 A, lanes 3–8). Furthermore, 3M/
APP with mutated positive residues at 
 
 
 
40, 
 
 
 
44, and
 
 
 
51, as shown in Fig. 1 A, was not imported significantly
(Fig. 2 A, lanes 9 and 10), suggesting the importance of
these residues for mitochondrial targeting. The possibility
of the acidic domain spanning amino acids 220–290 im-
posing a barrier for complete translocation was verified by
using a deletion mutant of APP lacking this domain (Fig. 1
A, 
 
 
 
220–290/APP). The 
 
 
 
220–290/APP protein was com-
Figure 2. Mitochondrial targeting of APP under in vitro and in 
vivo conditions. (A, B and C) WT/APP, 3M/APP,  220–290/APP, 
P450 MT2 ( 33/1A1), and P450 MT4 (2B1) proteins were used for 
the in vitro transport in isolated rat brain mitochondria as described 
in the Materials and methods using 250  g trypsin/ml of reaction 
( ). (A, lanes 4–6) Mitochondria were preincubated with or without added inhibitors (50  M CCCP or 50  M 2,4 DNP) at 25 C for 10 min 
before initiating the in vitro transport. (C) Mitochondria were treated with 0.1% Triton X-100 before treatment with trypsin. In each case, 
200  g of mitochondrial protein was used for electrophoresis, and the gels were subjected to fluorography. (D–G) In vivo targeting of WT/APP, 
3M/APP, and  220–290/APP. HCN-1A cells were transfected with WT/APP (D and G), 3M/APP (E), and  220–290/APP (F) cDNA constructs, 
and PM and mitochondrial fractions were probed with APP Ct Ab (D–F) and APP Nt Ab (G). Trypsin treatment was performed as in A. 
Treatment with digitonin and extraction with 0.1 M Na2CO3 (D, lanes 9 and 10) were performed as described in the Materials and methods. 
P, pellet; S, supernatant.T
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pletely internalized by mitochondria, as indicated by the
protection of nearly the full-length of input protein by
trypsin (Fig. 2 A, lanes 11 and 12). Control experiments in
Fig. 2 C show that the 22-kD protease-protected fragment
is located inside the mitochondrial membranes because dis-
ruption of membrane by Triton X-100 (0.1%) rendered the
protein sensitive to protease. Furthermore, labeled APP
protein in reactions without added mitochondria was com-
pletely sensitive to trypsin, dispelling the possibility that re-
sistance to protease was due to some unusual structural fea-
tures of the protein. These results together show that APP is
targeted to mitochondria, although the acidic domain con-
taining 70 negatively charged residues likely imposes a
structural barrier for the complete translocation of APP into
the mitochondrial compartment.
The bimodal targeting of APP695 in vivo was studied by
transfection of HCN-1A neuronal cells with WT/APP,
3M/APP, and 
 
 
 
220–290/APP cDNAs. PM and mitochon-
drial proteins from transfected cells were subjected to
immunoblot analysis. Both intact and digitonin-treated
mitochondria from transfected cells contained significant
putative nonglycosylated 95-kD APP (25–30% of the total
pool; Fig. 2 D, lanes 3 and 5–7). Mitochondria treated with
trypsin showed a 22-kD antibody-reactive fragment (lane
4). Digitonin treatment, which strips off the outer mem-
brane, did not reduce the level of 95-kD protein (Fig. 2 D,
lanes 5–7), suggesting its association with the inner mem-
brane matrix compartment. Trypsin treatment of digitonin-
treated mitochondria resulted in a slight reduction in the
size of protected fragment by 
 
 
 
1–2 kD (Fig. 2 D, lane 8),
which may account for the region spanning the intermem-
brane space of translocation-arrested protein. Resistance to
alkaline Na
 
2
 
CO
 
3
 
 extraction (Fig. 2 D, lanes 9 and 10) of
mitochondrial-associated APP further supports its trans-
membrane topology. Mutations targeted to the three posi-
tively charged residues (3M/APP) completely abolished
mitochondrial targeting, though the mutant protein was ef-
ficiently targeted to the PM (Fig. 2 E). A deletion construct
lacking the acidic domain (
 
 
 
220–290/APP), however, was
targeted to both the PM and mitochondria (Fig. 2 F). In
agreement with the results of in vitro mitochondrial import
in Fig. 2 A, the entire length of the 
 
 
 
220–290/APP protein
was protected by protease treatment, suggesting that it is
completely internalized by mitochondria (Fig. 2 F, last
lane). Finally, the C
 
out
 
 orientation of the mitochondrial
transmembrane-arrested APP was verified using an anti-
body specific for the COOH-terminal end of APP (APP Ct
Ab). As shown in Fig. 2 G, APP Ct Ab cross-reacted with
intact 95-kD mitochondrially associated APP but failed to
interact with the protease-protected 22-kD fragment, con-
firming the N
 
in
 
 orientation. These results further demon-
strate that mitochondrially targeted APP occurs in a trans-
membrane-arrested orientation with the NH
 
2
 
 terminus
buried inside mitochondria.
The dual localization of APP695 in mitochondria and the
PM was further investigated by immuno-colocalization of
Figure 3. Subcellular localization of WT/APP and 3M/APP by 
immunofluorescence microscopy. HCN-1A cells (A–L) and COS 
cells (M–R) were transfected with WT/APP (A–F) or 3M/APP (G–L). 
The inset in F is a twofold enlargement of a region showing APP 
Ab–stained granular structures both overlapping and nonoverlapping 
with mitochondrial stain, as indicated by arrows. Nonpermeabilized 
cells (A–C, G–I, and M–O) were double immunostained with APP 
Nt Ab and monoclonal antibody to Na
 / K
  ATPase. Permeabilized 
cells (D–F, J–L, and P–R) were double stained with APP Nt Ab and 
rabbit polyclonal antibodies to TOM40. Staining patterns (A, B, D, 
E, G, H, J, K, M, N, P, and Q) were developed with appropriate 
secondary antibodies conjugated to Alexa dyes. (C, F, I, L, O, and R) 
Respective overlay patterns.T
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the protein in HCN-1A cells transfected with WT/APP and
3M/APP cDNA constructs for 24 h. Triton-permeabilized
cells were subjected to double immunostaining with APP Nt
Ab and antibody to mitochondrial outer membrane receptor
TOM40. Nonpermeabilized cells were immunostained with
APP Nt Ab and antibody to the PM-specific marker Na
 
 
 
/
K
 
 
 
 ATPase. In nonpermeabilized cells transfected with WT/
APP, a robust staining around the PM by APP antibody was
observed (Fig. 3 A), which colocalized with Na
 
 
 
/K
 
 
 
 ATPase
(Fig. 3, B and C). In permeabilized cells, the APP Nt Ab
stained extranuclear granulate structures (Fig. 3 D), some
of which colocalized with mitochondrial-specific marker
TOM40 (Fig. 3, E and F). The inset in Fig. 3 F shows a re-
gion of the cell with high mitochondrial content, which
shows APP-stained structures both overlapping and non-
overlapping with mitochondrial-specific stain. These results
show that ectopically expressed APP is targeted to both the
PM (through the ER route) and mitochondria. Predictably,
transfection with 3M/APP cDNA yielded predominantly
PM-specific staining (Fig. 3, G–I) and also some intracellu-
lar staining that did not colocalize with TOM40 stains (Fig.
3, J–L). The level of accumulation of APP in the Golgi ap-
paratus after 48 h of transfection was generally higher in
HCN-1A cells overexpressing WT/APP than in cells overex-
pressing 3M/APP (unpublished data). Reasons for this dif-
ference currently remain unclear.
The generality of observations with HCN-1A cells were
tested in COS cells transfected with WT/APP cDNA for 24 h.
As expected, in intact cells, the antibody stained the PM
fraction similar to that in HCN-1A cells (Fig. 3, M–O).
In permeabilized cells, the APP Nt Ab stained extranu-
clear  punctuate structures, which colocalized with mito-
chondrial-specific marker TOM40 (Fig. 3, P–R). Although
not shown, immunoblot analysis showed the presence of a
95-kD antibody-reactive protein in mitochondria from trans-
fected COS cells. A more punctate mitochondrial staining was
observed in COS cells versus more granular structures in
HCN-1A cells, probably reflecting cell-specific differences.
 
Association of transmembrane-arrested APP with 
mitochondrial translocases
 
Interaction of nascent proteins with mitochondrial outer
and inner membrane translocase complexes (TOMs and
TIMs, respectively) is a critical requirement for mitochon-
drial import of proteins. Because of the dynamic nature of
the transport process, the association of nascent proteins
with TOMs and TIMs is detectable only by generating
translocation intermediates using fusion proteins with dihy-
drofolate reductase (DHFR) in the presence of added meth-
atrexate (MTX), a ligand of DHFR (Eilers and Schatz,
1986). To test the association of APP with translocase pro-
teins, we generated a fusion construct consisting of the
1–220 amino acid region of APP fused to DHFR (Fig. 4 A).
As shown in Fig. 4 A, the 20-kD DHFR is not imported
significantly into mitochondria. However, the 1–220/APP–
DHFR fusion protein (42 kD) is imported into mitochon-
dria and rendered resistant to trypsin. In a reaction mixture
with added MTX, a 22-kD fragment of the fusion protein is
protected, suggesting that only part of the fusion protein en-
ters due to the ligand-mediated translocation arrest.
 
Fig. 4 B shows the extent of interaction of the 1–220/
APP–DHFR fusion protein with various translocase pro-
teins, as determined by chemical cross-linking followed by
immunoprecipitation. The fusion protein from an in vitro
reaction mixture without added cross-linker is immunopre-
cipitated by APP Nt Ab but not by pre-immune Ab. The
APP Nt Ab also yielded a 42-kD immunoprecipitate with
no detectable cross-linked product from a reaction mixture
without added MTX, probably reflecting the dynamic na-
ture of the import process. A reaction mixture with added
MTX, however, yielded two major cross-linked products (82
and 62 kD) in addition to the 42-kD input protein with Nt
Ab. The 82- and 62-kD products were not seen in reactions
without added cross-linker. Immunoprecipitation with anti-
bodies specific for different translocase proteins shows that
the 82-kD band represents cross-linked products with
TOM40 and TIM44, both of which have nearly comparable
molecular mass. The 62-kD component represents cross-
linked product with TIM23. These results show that the
NH
 
2
 
-terminal 220–amino acid sequence of APP can indeed
direct the mitochondrial targeting of a nonmitochondrial re-
porter protein, DHFR, and that it interacts with mitochon-
drial translocase proteins.
Fig. 4 C shows the cross-linked products of translocation-
arrested APP with mitochondrial translocase complexes. It is
seen that reaction with 
 
 
 
220–290/APP, which is trans-
ported into mitochondria without any translocation arrest,
predominantly yielded the input protein without any detect-
able higher molecular forms. Reactions with WT/APP, on
the other hand, yielded three higher molecular weight com-
ponents of 
 
 
 
110, 120, and 140 kD with APP Nt Ab. Im-
munoprecipitation with antibodies against specific translo-
case proteins indicated that the 140-kD species consists of
APP cross-linked to TOM40 or TIM44, whereas the 120-
kD species represents cross-linked product with TIM23.
The nature of the 110-kD species remains unclear, though it
may represent cross-linked products with some of the
smaller TOM or TIM proteins. These results provide confir-
matory evidence that the mitochondrial-associated WT/APP
exists in transmembrane-arrested form in association with
various translocase proteins.
A direct evidence for the transmembrane orientation of
mitochondrial-targeted APP was sought by immunoelec-
tron microscopy of HCN-1A cells transfected with WT and
mutant APP cDNAs for 32 h. We used primary antibodies
specific for the NH
 
2
 
 and COOH termini of APP and anti-
body for TOM40 simultaneously for probing the sections,
and costained with colloidal gold–conjugated secondary an-
tibodies, each specific for a given antibody. The anti–Nt
APP Ab was conjugated to 5-nm gold particles, anti–A
 
 
 
APP Ab to 10-nm gold, and anti-TOM40 Ab to 20-nm
gold particles. The electron micrograph in Fig. 4 D shows
that APP-specific (5 and 10 nm) electron-dense particles are
associated with mitochondria, the ER, the Golgi apparatus,
and secretory vesicles. Interestingly, the mitochondrial-
associated APP is organized in an N
 
in
 
–C
 
out
 
 orientation in-
variably in close proximity to TOM40 protein (20-nm
particle). The positions of the NH
 
2
 
- and COOH-terminal–
specific stains suggest that the APP protein is in direct con-
tact with, and possibly traversing, the channel-formingT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
46 The Journal of Cell Biology 
 
|
 
 
 
Volume 161, Number 1, 2003
Figure 4. Transmembrane-arrested APP exists in contact with 
mitochondrial translocase proteins. 
35S-labeled APP (1–220) fused 
to DHFR (APP–DHFR), WT/APP, or  220–290/APP proteins were 
used for in vitro transport with isolated yeast mitochondria, and 
translocation intermediates were cross-linked with MBS as described 
below. In indicated experiments, MTX (1  mol/ml of reaction) was 
added to generate translocation intermediates. Both the input and 
cross-linked products were immunoprecipitated with antibody to 
APP and then probed with indicated antibodies by immunoblot 
analysis. (A) In vitro transport of APP–DHFR fusion protein. Trypsin 
treatment (250  g /ml reaction) was performed for 20 min on ice as 
described in the Materials and methods. (B) Cross-linking of 
APP–DHFR fusion protein with yeast mitochondrial translocases. 
(C) Cross-linking of WT/APP and  220–290/APP with yeast 
mitochondrial translocase proteins. In vitro transport was performed 
with indicated proteins in the absence of added MTX. (D, E, and F) 
Immunoelectron microscopy of HCN-1A cells transfected with 
WT/APP, 3MAPP, and  22–290/APP, respectively, for 32 h. 
M, mitochondrion; G, Golgi; E, ER; N, nucleus; V, vesicles. 
Arrow 1, COOH terminus of APP (10-nm gold particle); arrow 2, 
TOM40 (20-nm gold particle); arrow 3, NH2 terminus of APP 
(5-nm gold particle).T
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TOM40 protein. As expected, APP associated with the
Golgi apparatus, the ER, and secretory vesicles showed only
APP NH
 
2
 
- (Fig. 4 D, arrow 3) and COOH-terminal A
 
 
 
(Fig. 4 D, arrow 1)–specific stains, but not TOM40-spe-
cific stain. In keeping with the results of immunoblot anal-
ysis and immunofluorescence microscopy (Fig. 2 E and Fig.
3, J–L), cells transfected with 3M/APP cDNA showed
vastly reduced mitochondrial localization but significant lo-
calization in the Golgi apparatus and transport vesicles (Fig.
4 E). Cells transfected with 
 
 
 
220–290/APP, on the other
hand, showed the distribution of COOH- (Fig. 4 E, arrow
1) and NH
 
2
 
-terminal (Fig. 4 E, arrow 3)–specific stains in
different subcellular compartments, including mitochon-
dria (Fig. 4 F). Interestingly, both the COOH- and NH
 
2
 
-
terminal–specific stains for 
 
 
 
220–290/APP protein were
localized well inside the mitochondrial inner membrane,T
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confirming that it is completely internalized. These results
show that mitochondrial-associated APP exists in a trans-
location-arrested orientation through the mitochondrial
membrane. Results also provide further confirmation that
the negatively charged domain is essential for causing the
translocation arrest of APP.
 
Inverse patterns of APP accumulation 
in the mitochondrial and PM fractions 
at longer time intervals
 
We next determined the time course of accumulation of
APP695 in the mitochondrial and PM fractions of HCN
cells transfected with WT/APP, 3M/APP, and 
 
 
 
220–290/
APP cDNA constructs and also the accumulation of the in-
tra- as well as the extracellular A
 
 
 
 peptide at these time
points (Fig. 5; Table I). Immunoblot in Fig. 5 A shows a
steady increase in the level of WT/APP in the mitochondrial
fraction from 0 to 96 h of transfection, whereas the level in
the PM declined steadily during this time (Fig. 5 B). Nota-
bly, the level of secreted A
 
 
 
 pool (A
 
 
 
40, 42, and 43) in the
culture fluid (CF) declined steadily (Fig. 5 C), in parallel to
declining APP in the PM fraction (Fig. 5 B). Use of peptide-
specific antibodies to A
 
 
 
40 and A
 
 
 
42 indicated that cells
transfected with 3M/APP cDNA excreted mostly A
 
 
 
40 pep-
tide, whereas cells transfected with WT/APP cDNA ex-
creted a mixture of A
 
 
 
40 and 42 peptides after 24 h (un-
published data). In cells transfected with 3M/APP, however,
no significant mitochondrial accumulation of APP was ob-
served (Fig. 5 E), though the level of PM-associated APP
and the secreted A  peptide (Fig. 5, F and G) increased with
time. Furthermore, cells transfected with  220–290/APP
showed a time-dependent increase in the accumulation of
mutant protein in both the mitochondrial (Fig. 5 I) and PM
(Fig. 5 J) compartments. This coincided with the increased
secretion of total A  in the culture fluid (CF) (Fig. 5 K). As
the Golgi network has been shown to be an important cellu-
lar site of A  production (Greenfield et al., 1999), we ex-
amined the level of the A  peptide in the purified Golgi
fraction of transfected cells. It is seen that by 48 h of trans-
fection, there was an increased accumulation of the peptide
in the Golgi apparatus of cells transfected with WT/APP
(Fig. 5 D). Surprisingly, accumulation of processed 4-kD
A  peptide in the Golgi apparatus did not occur in cells
transfected with 3M/APP and  220–290/APP constructs
Figure 5. Subcellular distribution of ectopically expressed APPs in HCN-1A cells. Cells were transfected with WT/APP (A–D), 3M/APP (E–H), 
 220–290/APP (I–L), and SW/APP (M–P). At indicated times after transfection, mitochondria (MITO.), PM, and Golgi fractions (50  g protein 
each) and also protein concentrate from 10 ml of cell-free culture medium (CM) were subjected to Western immunoblot analysis using 
antibodies to APP Nt (A, B, E, F, I, J, M, and N) or A  (C, D, G, H, K, L, O, and P). (Q) The level of expression of total APP protein in cells 
transfected with various cDNA constructs for different time points was monitored by immunoblot analysis of whole cell lysates. The antibody-
reactive proteins were quantified using a Bio-Rad Laboratories Fluoro S imaging system. Table I shows the distribution of APP in different 
membrane fractions at different time points after transfection with WT/APP and SW/APP cDNAs. Values at the bottom of Q show relative APP 
levels in comparison with the level at 24-h transfection that was considered to be 1. (R) Pulse chase characteristics of mitochondrial- and 
PM-associated APP. HCN-1A cells transfected with WT/APP cDNA for 24 h were labeled with [
35S]Met for 2 h, followed by a chase in normal 
growth medium containing 3 mM unlabeled Met. Mitochondrial and PM proteins from cells at different points of chase (500  g each) were 
immunoprecipitated with APP Nt Ab, analyzed by electrophoresis on 10% SDS-polyacrylamide gels, and imaged through a Bio-Rad Laboratories 
GS525 molecular imager. The immunoblot at the top of the figure was performed using 100  g protein from each fraction using APP Nt Ab.
Table I. Subcellular distribution of APP in cells transfected with WT/APP and SW/APP constructs
% Distribution of WT/APP % Distribution of SW/APP
Transfection (h) Mito PM CF Golgi Transfection (h) Mito PM CF Golgi
24 14.5 42 43 0.5 24 15 25 35 25
48 32.3 23.3 28 16.4 48 28 15 20 37
96 43 7.7 10 39.3 96 38 3 8 51
The distribution of antibody-reactive protein was determined by quantitation of immunoblots from Fig. 5 (A–D and M–P). The sum of band densities (Mito,
PM, CF, and Golgi) was taken as 100% for calculating the % distribution. Mito, mitochondria; CF, culture fluid.T
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(Fig. 5, H and L). We also tested the intracellular distribu-
tion of the Swedish mutant of APP (SW/APP), which is im-
plicated in familial AD (Selkoe, 1999). Fig. 5 (M–P) shows
that the pattern of accumulation of APP in mitochondria
and the PM and the level of secreted A  in the extracellular
compartment are nearly similar to those with WT/APP. The
only difference is the time frame of accumulation of 4-kD
A  peptide in the Golgi apparatus, which occurs at 24 h in
the case of SW/APP and 48 h in the case of WT/APP. These
results show that the levels of mitochondrial targeting of
WT/APP and SW/APP are nearly similar.
Total cell extracts from companion cells, as in Fig. 5 (A,
E, I, and M), were subjected to immunoblot analysis to de-
termine the level of expression of WT and mutant forms of
APP at various time points of transfection. Results in Fig. 5
Q show that the levels of expression of WT, 3M/APP, and
 220–290/APP at all time points were nearly comparable
with an  10–20% increase by 48 and 96 h as compared
with the 24 h time point. These results suggest that the ob-
served differences in the distribution of APP and A  peptide
levels in different cell compartments were not due to vastly
variable levels of transfection or expression.
The reason for the contrasting levels of APP in the mito-
chondrial and PM fractions at longer time intervals was veri-
fied by pulse chase experiments. After 24 h of transfection
with WT/APP cDNA, cells were labeled for 2 h with
[
35S]Met and chased for various time periods up to 16 h
(Fig. 5 R) by growing in a normal medium. APP protein
from the mitochondrial and PM fractions at each time point
was immunoprecipitated and resolved on an SDS gel, and
the radioactivity was quantified. Fig. 5 R shows that the ra-
dioactivity in the mitochondrial-associated APP increased
steadily up to 16 h of chase, whereas the radioactivity in the
PM fraction declined steadily. The steady-state APP levels in
the mitochondrial and PM fractions, as indicated in the im-
munoblot at the top, essentially concur with the pulse chase
pattern. These results show that the pools of APP from the
mitochondria and PM are turned over quite differently and
provide a rational basis for the observed differences in the
steady-state levels of APP in the two compartments at 48
and 96 h after transfection.
Accumulation of transmembrane-arrested APP disrupts 
mitochondrial functions
To understand the patho-physiological relevance of the mi-
tochondrial accumulation of APP in a transmembrane-
arrested orientation, we assessed mitochondrial functional
parameters. A time-dependent accumulation of APP in the
mitochondria of cells transfected with WT/APP was accom-
panied by a decline in the CytOX activity (Fig. 6 A), mark-
edly reduced respiration-coupled (mitochondrially gener-
ated) ATP synthesis (Fig. 6 B), a decline in total cellular
ATP levels (Fig. 6 C), and disruption of mitochondrial
transmembrane potential (Fig. 6 D). These functional pa-
rameters were progressively reduced to 50–80% of control
cells transfected with vector DNA alone (Fig. 6, A–D).
Transfection with 3M/APP (which showed no detectable
mitochondrial accumulation) and  220–290/APP (which
did not cause translocational arrest), however, showed no ef-
fect on the cellular or mitochondrial ATP pools, CytOX ac-
tivity, or transmembrane potential (Figs. 6, A–D). Trans-
fection with SW/APP with intact NH2-terminal signal
sequence and the acidic domain affected mitochondrial
functional parameters at levels similar to that with WT/
APP. These results show, for the first time, the progressive
nature of mitochondrial accumulation of transmembrane-
arrested APP and its adverse effects on energy production in
cells overexpressing the protein.
Transmembrane-arrested APP and impaired energy 
metabolism in brain mitochondria from a mouse model 
for AD
AD-like plaque pathology was uniformly observed in trans-
genic mouse models expressing higher levels of human APP
protein (for review see Janus and Westaway, 2001). To un-
derstand the physiological significance of our results with
transfected cells, we analyzed the subcellular distribution of
Figure 6. Effects of transmembrane-arrested APP on mitochondrial 
functions. Total cell extracts or mitochondria from HCN-1A cells 
transfected with WT/APP, 3M/APP,  220–290/APP, and SW/APP 
were analyzed for CytOX activity (A), mitochondria and total 
cell ATP generation (B and C, respectively), and changes in the 
mitochondrial membrane potential using MitoTracker orange 
CM-H2TM ROS (D), as described in the Materials and methods. 
Mitochondrial CytOX activity (2 nmol of cytochrome c oxidized/
min/mg mitochondrial protein) from vector alone–transfected cells 
was used as 100% activity. Values represent mean   SEM from 
three separate transfection experiments.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
50 The Journal of Cell Biology | Volume 161, Number 1, 2003
APP in the brains of transgenic mice overexpressing SW/
APP (2576). PM and mitochondria from cortex, hippo-
campus, and cerebellum regions of brains from 12-mo-old
amyloid plaque–bearing transgenic mice were isolated and
compared with similar regions of age-matched controls.
The immunoblot in Fig. 7 A (bottom) shows that the anti-
body-reactive APP levels in the PM from the cortex, hip-
pocampus, and cerebellar regions of brains from control
and transgenic mice were nearly comparable. But the mito-
chondrial fractions of corresponding mouse brain regions of
transgenic mice showed markedly elevated APP compared
with counterparts from control brains (Fig. 7 A, top). The
cortex and hippocampal regions of transgenic mice con-
tained considerably higher levels of mitochondrial-associ-
ated APP compared with the cerebellum. Furthermore,
trypsin treatment of mitochondria from different brain re-
gions of transgenic mice yielded a 22-kD protected frag-
ment of APP (Fig. 7 B). These results suggest a transmem-
brane-arrested topology of mitochondrial-associated APP in
transgenic mouse brain similar to that observed in HCN-
1A cells transfected with WT/APP cDNA. Increased mito-
chondrial association of APP in the transgenic mouse model
was accompanied by a 20–40% decrease in the CytOX ac-
tivity (Fig. 7 C) and a 25–50% reduction in total cellular
ATP levels (Fig. 7 D) in the cortex and hippocampus. The
cerebellar region with a relatively lower level of mitochon-
drial-associated APP showed a less severe inhibition of Cy-
tOX activity (Fig. 7 C) and ATP pool (Fig. 7 D). These re-
sults confirm that in both APP-expressing HCN-1A cells
and mouse brain, mitochondria are the direct targets of this
pathogenic protein.
Discussion
AD is associated with multiple lesions including reduced
ATP synthesis and altered mitochondrial structure and func-
tion in the brain. It is not clear whether the AD-associated
mitochondrial defects are contributing factors in the pro-
gression of the disease. A general change in glucose utiliza-
tion, increased oxidative stress, and Ca
2  deregulation are
additional metabolic defects in the AD brain that may also
be associated with defective mitochondrial function (Sims,
1996; Beal, 1998). However, the precise mechanism of mi-
tochondrial pathology in AD remains unclear. In this study,
we demonstrate for the first time that incomplete transloca-
tion and progressive accumulation of APP on mitochondrial
membranes is the major cause of mitochondrial dysfunction.
The APP cDNA constructs and proteins used in this study
contained an intact COOH-terminal end, which contrib-
utes to the toxic A  peptide as mutations were exclusively
targeted to the NH2-terminal signal sequence or the 70–
amino acid-long acidic region. Additionally, as shown in
Fig. 5 Q, transfection conditions were standardized to yield
nearly comparable levels of expression. We also used a non-
transformed human neuronal HCN-1A cell line whose neu-
rochemical and morphological characteristics have been well
documented. These cells resemble the human primary corti-
cal neuronal cells and are suitable for studying neurodegen-
erative disorders (Ronnett et al., 1990; Dunn et al., 1996).
Essentially similar mitochondrial accumulation of trans-
membrane-arrested APP and altered mitochondrial oxida-
tive functions were observed in brain regions of a transgenic
mouse model for AD, suggesting the physiological relevance
of our findings.
The concept of chimeric NH2-terminal signals that direct
the bimodal targeting of proteins to both the ER and mito-
chondria emerged from our recent studies on the targeting
of cytochromes P4501A1, 2B1, and 2E1 (Addya et al.,
1997; Anandatheerthavarada et al., 1999; Robin et al.,
2002). The prevailing view up to this point was that cyto-
plasmically translated proteins are targeted either to the ER
or to mitochondria by virtue of specific NH2-terminal sig-
nals they carry. In our search for other cellular proteins con-
taining similar bimodal targeting signals, we found that the
NH2 terminus of APP resembles the chimeric signal of
Figure 7. Mitochondrial-associated APP in the brains of transgenic 
mice overexpressing APP. (A) Mitochondria and PM fractions from 
different brain regions of control and SWEAPP (2576) transgenic 
mice (50  g protein each) were subjected to immunoblot analysis 
using APP Nt Ab. (B) Mitochondria (50  g) from different brain 
regions of transgenic mice overexpressing SW/APP (SWEAPP [2576]) 
were subjected to trypsin treatment (as described in Fig. 2) followed 
by immunoblot analysis with APP Nt Ab. (C) CytOX activity in 
total mitochondrial membrane fraction and (D) total cellular ATP 
levels were assayed as described in the Materials and methods. 
MITO., mitochondria; Ctl, control; Tg, transgenic; Ct, cortex; 
Hp, hippocampus; Ce, cerebellum.T
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P4501A1, 2B1, and 2E1. Our results using both in vivo tar-
geting by ectopic expression of APP in whole cells as well as
in vitro transport in isolated brain mitochondria demon-
strate that the three positively charged residues at  40,
 44, and  51 of APP are critical for mitochondrial target-
ing. Mitochondrial localization of APP in transiently trans-
fected HCN-1A cells is not an artifact of overexpression, as
PMA-mediated induction of endogenous gene expression in
HCN-1A cells resulted in the accumulation of APP in the
mitochondrial compartment and a corresponding inhibition
of mitochondrial function. Translocation-arrested APP–
DHFR fusion protein interacts efficiently with mitochon-
drial inner and outer membrane translocase proteins
TOM40, TIM23, and TIM44 (Truscott et al., 2001), as
tested by chemical cross-linking, which provides direct sup-
port for mitochondrial targeting of APP. A similar mito-
chondrial transmembrane-arrested APP pool and altered
mitochondrial function were observed in brains of APP-
overexpressing mice that have been used as models for AD.
Furthermore, mitochondrial targeting of APP is not re-
stricted to neuronal cells because COS cells overexpressing
this protein also show mitochondrial localization.
Protection of a 22-kD fragment against proteolytic diges-
tion initially suggested that the mitochondrially targeted
APP in HCN-1A cells as well as in the brains of transgenic
mice exists in a translocation-arrested orientation. The arrest
region maps to the 70–amino acid-long acidic domain,
which is implicated in Zn
2  binding and functional interac-
tion with other proteins (Takahashi et al., 2000). The trans-
mitochondrial membrane arrest and also the role of the
acidic domain in causing the arrest were investigated by two
different approaches. In the first approach, the use of WT/
APP with an intact acidic domain for in vitro import into
isolated mitochondria yielded translocation intermediates
that could be cross-linked with mitochondrial inner and
outer membrane translocases (Fig. 5 C). The  220–290/
APP protein with deleted acidic domain, on the other hand,
failed to produce cross-linked products with translocase pro-
teins, suggesting the role of the acidic domain in transloca-
tion arrest. The second approach involved immunoelectron
microscopy of transfected HCN-1A cells, which demon-
strates contrasting modes of mitochondrial membrane asso-
ciation of WT/APP and  220–290/APP, lacking the acidic
domain. Results conclusively show that mitochondrial-tar-
geted APP exists in an Nin–Cout transmembrane-arrested to-
pology and that transmembrane-arrested protein is either in
direct contact with, or traversing through, TOM40 translo-
case. The immunoelectron microscopy results (Fig. 4 D)
show that nearly 80% of antibody-stained TOM40 com-
plexes along the mitochondrial outer membrane are engaged
by APP. These results lead us to believe that blocking of mi-
tochondrial protein transport channels by transmembrane-
arrested APP is a major contributing factor in the impair-
ment of mitochondrial functions and decreased cellular
energy levels. In support of this view, NH2-terminal muta-
tions that affected mitochondrial targeting or deletion of the
acidic domain that abolishes translocation arrest did not
cause adverse effects on any of the mitochondrial functions
tested. This is probably the first demonstration of transloca-
tion arrest causing mitochondrial perturbation in any bio-
logical system. We believe that the structural features of this
domain impose a barrier for complete translocation. The
inability of cytoplasmic chaperones to fully unfold the
polypeptide at this domain might be the cause of transloca-
tion arrest of APP. An alternative possibility is that the nega-
tively charged domain fails to bind efficiently to the nega-
tively charged channel-forming outer membrane protein
TOM22 because of electrostatic repulsion.
In support of previous studies (Hatanpaa et al., 1998;
Webster et al., 1998), our results show that increased pro-
duction of extracellular A  peptide in cells overexpressing
the 3M/APP and  220–290/APP mutant proteins did not
cause changes in mitochondrial function or ATP synthesis.
The accumulation of A  in the Golgi network might be di-
rectly related to reduced APP trafficking to the PM and de-
creased A  secretion in cells transfected with WT/APP.
These results are in agreement with the view that accumu-
lation of COOH-terminal fragments in the intracellular
compartments impairs A  secretion and APP traffick-
ing (Greenfield et al., 1999; Maltese et al., 2001). How-
ever, expression of 3M/APP and  220–290/APP mutant
proteins that failed to cause mitochondrial dysfunction
showed no accumulation of A  peptides in the Golgi net-
work, suggesting that mitochondrial function may some-
how be associated with the accumulation of toxic A 
peptides in the secretory pathway. Although the precise
relationship between mitochondrial injury and altered traf-
ficking of cargo through the Golgi network remains un-
Figure 8. A proposed model for the mitochondrial 
targeting and accumulation of transmembrane-
arrested APP affecting mitochondrial functions.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
52 The Journal of Cell Biology | Volume 161, Number 1, 2003
known, our results are in line with a previous study im-
plicating the role of mitochondrial function in the
accumulation of COOH-terminal fragments of APP in the
secretory pathway (Busciglio et al., 2002). Based on these,
we propose a model (Fig. 8) for the bimodal targeting of
APP through its NH2-terminal chimeric signal. We further
propose that under increased APP expression, a progressive
accumulation of transmembrane-arrested APP causes per-
turbation of mitochondrial function, which in turn results
in impairment of energy metabolism.
Studies on overexpression of WT/APP either by transient
transfection or by stable expression in cell types including
neuronal cells have noted growth defects and mitochondrial
structural abnormalities (Nishimura et al., 1998; Grant et
al., 1999; Uetsuki et al., 1999; Campard et al., 2000). It is
thought that the threshold of expression of WT/APP needed
to cause cellular abnormality is relatively higher than that
with APP bearing familial Alzheimer’s mutations (Hasimoto
et al., 2000). The threshold level of APP expression needed
for the pathogenic outcome also appears to be related to spe-
cies variations, as humans with trisomy express only twofold
higher levels of WT/APP and yet invariably develop AD pa-
thology by 30–40 yr of age (Teller et al., 1996). However, a
fivefold higher expression of familial AD mutant APP, in-
cluding SW/APP, is required to induce AD-like pathology
in mice (for review see Janus and Westaway, 2001). Results
of cDNA transfection in HCN-1A cells (Figs. 5 and 6) show
that the extent of mitochondrial targeting and causation of
mitochondrial injury are comparable with both WT/APP
and SW/APP. It is therefore likely that increased mitochon-
drial accumulation and associated mitochondrial toxicity are
contributing factors in the pathogenesis of the AD-like syn-
drome in the SW/APP-overexpressing animal model ana-
lyzed in this study. In summary, we show a novel mode of
APP targeting to mitochondria, which may contribute to the
pathogenic outcome, especially in the APP-overexpressing
neuronal cells.
Materials and methods
Protein transport into isolated mitochondria
In vitro import of 
35S-labeled proteins into isolated rat liver mitochondria
was performed as described before (Addya et al., 1997). cDNAs encoding
the SW/APP (K595N and M596L), 3M/APP, and  220–290/APP were gen-
erated using pCB695 as the template and cloned into TA vector. 
35S-labeled
translation products were generated in a transcription-coupled translation
system (Promega). Import of the in vitro–synthesized proteins was per-
formed in a 200- l volume (Addya et al., 1997), in some cases with added
inhibitors CCCP (50  M) and 2,4 DNP (50  M). Swelling was caused by
suspending mitochondria in a hypotonic buffer (Addya et al., 1997). In
vitro–incubated mitochondria were subjected to trypsin treatment (250  g/
ml of reaction) and pelleted through 1 M sucrose. Mitochondrial proteins
were separated by SDS-PAGE and subjected to fluorography.
Cell transfection and subcellular localization of proteins
HCN-1A neuronal cells derived from human cortex (American Type
Culture Collection) were grown in DME (pH 7.35) containing 4 mM
L-glutamate, 1.5 g/L sodium carbonate, and 10% FBS. Cells were trans-
fected with WT/APP, and mutant cDNAs were cloned into mammalian
expression vector pCMV4 (5  g/plate) using Fugene at 50% confluence.
Cells were harvested and homogenized (35–40 strokes) in four volumes
of homogenization buffer (250 mM sucrose, 10 mM Tris-HCl, pH 7.4,
and 1 mM MgCl2) using a Teflon-fitted glass homogenizer. The homoge-
nate was centrifuged at 1,500 g for 20 min, and the resulting pellet was
used for isolating the PM as previously described (Dasso, 1998). The
1,500 g supernatant fraction was used to isolate mitochondria by sucrose
density banding as described before (Addya et al., 1997). Golgi and ER
fractions were isolated from post-mitochondrial supernatant (Dasso,
1998). The purity of the PM and mitochondrial fraction was assessed by
enrichment of marker proteins. In some experiments, mitochondria from
transfected cells were subjected to protease protection assay, digitonin
fractionation, and 0.1 M Na2CO3 (pH 11) extraction as described before
(Anandatheerthavarada et al., 1999).
Immunoblot and Northern blot analysis
Proteins were resolved by electrophoresis through 10% SDS-polyacryl-
amide gels or 12% Tricine gels and transferred to nitrocellulose membrane.
Immunoblots were developed with rabbit polyclonal antibodies directed
against the COOH-terminal 22–amino acid sequence of APP (APP Ct Ab),
the A  Ab (Zymed Laboratories) raised against the 1–40/42 A  region of
APP, or goat polyclonal antibody against sequence 44–63 of APP (APP Nt
Ab) (Calbiochem). The blots were developed using the Pierce Super Signal
ULTRA chemiluminescence substrate kit, and the protein bands were
quantitated in a Bio-Rad Laboratories FluorS imaging system. Total RNA
(25   g) was subjected to Northern hybridization using oligonucleotide
probes specific to APP695 (Shepherd et al., 2000) by standard conditions.
Indirect immunofluorescence microscopy
HCN-1A cells grown on coverslips were transfected with various cDNA
constructs for 32 h and processed for antibody staining as previously de-
scribed (Addya et al., 1997). Cells permeabilized with 0.1% Triton X-100
were stained with APP Nt Ab and rabbit polyclonal antibody to TOM40.
Nonpermeabilized cells were stained with APP Nt Ab and a mouse mono-
clonal antibody to Na
 /K
  ATPase as a marker for PM. The cells were then
stained with appropriate fluorescence-tagged secondary antibodies and
subjected to confocal fluorescence microscopy (Leica).
Measurement of CytOX activity and ATP levels
ATP levels were measured using a somatic cell ATP assay kit (Sigma-
Aldrich). Mitochondria and total cell lysates were mixed with ATP-releas-
ing reagent and assayed for luciferase activity as per the manufacturer’s
protocol in a TD-20/20 luminometer (Turner Designs). COX activity was
measured essentially as previously described using ferrocytochrome c as
substrate (Vijayasarathy et al., 1999).
Protein deglycosylation assay
Membrane proteins (200  g) were deglycosylated in 50  l of 100 mM Tris-
HCl buffer, pH 8.6, with 2 mU of PNGase F (Roche) at 37 C for 12 h. The
membranes were reisolated and suspended in 100 mM sodium citrate
buffer, pH 6.0, containing 0.1% SDS and 1% NP-40 and 2 mU O-glycanase
(Roche). After overnight incubation at 37 C, the reaction mixture was mixed
with 0.2 volumes of 5  Laemmli’s buffer and subjected to SDS-PAGE.
Isolation of brain regions from APP-overexpressing mice
Cortex, hippocampus, and cerebellum were dissected using anatomical
landmarks from 12-mo-old transgenic APPSWE (2576) and age-matched
control mice (B6SJLF1) purchased from Taconic. Tissue was pooled from
three animals from each group. Mitochondria and PM from the pooled tis-
sue were isolated as described above.
MTT reduction assay
The conversion of MTT to formazan by mitochondria was performed ac-
cording to Duan et al. (1999). Mitochondria (200  g protein) were incu-
bated with MTT dye (0.5 mg/ml) in a 400- l reaction volume at 37 C for
90 min. After the incubation, mitochondria were isolated and suspended
in DMSO (100%), and the absorbance of the solution was measured spec-
trophotometrically at 592 nm.
Measurement of mitochondrial membrane potential
Measurements were performed spectrofluorometrically in cell suspension
essentially as described by Amuthan et al. (2002). The membrane poten-
tial was measured as a function of mitochondrial uptake of MitoTracker
orange CM-H2TM ROS (50 nM) added to the cell suspension. Fluores-
cence was monitored in a multiwavelength excitation dual wavelength
emission Delta RAM PTI spectrofluorometer at 525 nm excitation and
575 nm emission.
Immunoelectron microscopy
HCN-1A cells transfected with various cDNAs for 32 h were fixed in 20
mM phosphate buffer containing 4% formaldehyde and 2% glutaralde-T
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hyde. Cells were dehydrated through a graded ethanol series and embed-
ded in hard grade LR White resin. Ultrathin sections, mounted on nickel
grids, were blocked with 20% FBS in TBS for 30 min at room temperature.
The sections were incubated with APP Nt Ab (anti–goat) and APP A  Ab
(anti–mouse) as well as antibody to TOM40 (anti–rabbit) for 24 h at 4 C.
The grids were rinsed with TBST for 15 min and incubated with anti–goat
(5 nm), anti–mouse (10 nm), and anti–rabbit (20 nm) colloidal gold–conju-
gated IgGs. Finally, the grids were stained with a saturated suspension of
aqueous uranyl acetate. The sections were examined and photographed in
a JEOL JEM-1010 electron microscope.
Metabolic labeling
HCN-1A cells transfected with wild-type APP695 for 24 h were initially la-
beled with [
35S]methionine (400  Ci/ml in methionine-free DME plus 5%
dialyzed FBS) for 2 h. This was followed by a change of medium to normal
DME with FBS and additional growth for 2–16 h at 37 C. Mitochondria
and PM were isolated from cells at each time point of chase, and 500  g of
each protein was immunoprecipitated with antibodies to APP Nt Ab at 4 C
by adsorption to protein A–agarose beads (Anandatheerthavarada et al.,
1999) and resolved by electrophoresis on 10% SDS-polyacrylamide gels.
The gels were dried and imaged through a Bio-Rad Laboratories GS-525
radiometric imager.
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